Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal;Relative Wirksamkeit und Verträglichkeit von Etoricoxib, Celecoxib und Naproxen bei der Behandlung von Osteoarthritis: Eine bayessche Netzwerkmetaanalyse randomisiert-kontrollierter Studien auf Basis von Patientenausschlüssen

Zeitschrift fur Rheumatologie

Volumn 75, Issue 5, 2016, Pages 508-516

  Song, Gwan Gyu ^a   Seo, Young Ho ^a   Kim, Jae Hoon ^a   Choi, Sung Jae ^a   Ji, Jong Dae ^a   Lee, Young Ho ^a  

^a College of Medicine   (South Korea)

Author keywords

Celecoxib; Etoricoxib; Meta analysis; Naproxen; Osteoarthritis

Indexed keywords

CELECOXIB; ETORICOXIB; NAPROXEN; ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; SULFONE;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MEDICAL DECISION MAKING; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; BAYES THEOREM; DOSE RESPONSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BAYES THEOREM; CELECOXIB; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES; TREATMENT OUTCOME;

EID: 84954307109     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-015-0023-9     Document Type: Article

References (34)

1. Dieppe PA, Lohmander LS (2005) Pathogenesis and management of pain in osteoarthritis. Lancet 365:965–973
2. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474
3. Mizuno K, Yamamoto S, Lands W (1982) Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. Prostaglandins 23:743
4. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115:787–796
5. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284:1247–1255
6. Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS (2005) Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial. Bmc Musculoskelet Disord 6:58 (NCT00242489)
7. Yoo MC, Yoo WH, Kang SB, Park Y-W, Kim SS, Moon KH, Song YW, Min BW, Cho YJ, Moon S-H (2014) Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. Curr Med Res Opin 30:2399–2408
8. Bingham C, Sebba A, Rubin B, Ruoff G, Kremer J, Bird S, Smugar S, Fitzgerald B, O’Brien K, Tershakovec A (2007) Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 46:496–507
9. Reginster J-Y, Malmstrom K, Mehta A, Bergman G, Ko A, Curtis S, Reicin A (2007) Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66:945–951
10. Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinstian A (2015) Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res 20:24
11. Choy E, Smith C, Dore C, Scott D (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414–1421
12. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D (1996) Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 276:637–639
13. Ravindran V, Scott D, Choy E (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859
14. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38:3643–3651
15. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27:827–833
16. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489–1496
17. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
19. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
20. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL. Syst Rev 3:110
21. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171
22. Yoo MC, Yoo WH, Kang SB, Park YW, Kim SS, Moon KH, Song YW, Min BW, Cho YJ, Moon SH, Bin SI, Baek HJ, Shim SC, Lee SW, Yoo DH, Mehta A, Skuban A, Cukrow DM, Vandormael K, Yan L (2014) Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. Curr Med Res Opin 30:2399–2408
23. Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O’Brien K, Tershakovec AM (2007) Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 46:496–507
24. Lisse J, Espinoza L, Zhao SZ, Dedhiya SD, Osterhaus JT (2001) Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. The journals of gerontology Series A. Biol Sci Med Sci 56:M167–175
25. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095–1105
26. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS (2001) Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 29:467–479
27. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, Castro R, Sanchez M, Detora LM, Ng J (2002) Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 18:49–58
28. Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS (2007) Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66:945–951
29. Essex MN, Bhadra P, Sands GH (2012) Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res 40:1357–1370
30. Lee YH, Woo J-H, Choi SJ, Ji JD, Song GG (2010) Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 30:357–363
31. Moore A, Makinson G, Li C (2013) Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther 15:R6
32. Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS (2005) The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 21:715–722
33. Varas‐Lorenzo C, Riera‐Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez‐Gutthann S (2013) Myocardial infarction and individual nonsteroidal anti‐inflammatory drugs meta‐analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559–570
34. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AM, Madsen OR, Torp-Pedersen C, Hansen PR (2013) Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 73:1515–1521. doi:10.1136/annrheumdis-2012-203137